Role of acetyl-L-carnitine in the brain: revealed by Bioradiography

Biochem Biophys Res Commun. 2003 Jul 11;306(4):1064-9. doi: 10.1016/s0006-291x(03)01103-3.

Abstract

To elucidate the role of acetyl-L-carnitine in the brain, we used a novel method, 'Bioradiography,' in which the dynamic process could be followed in living slices by use of positron-emitter labeled compounds and imaging plates. We studied the incorporation of 2-[18F]fluoro-2-deoxy-D-glucose ([18F]FDG) into rat brain slices incubated in oxygenated Krebs-Ringer solution. Under the glucose-free condition, [18F]FDG uptake rate decreased with time and plateaued within 350 min in the cerebral cortex and cerebellum, and the addition of 1 or 5mM acetyl-L-carnitine did not alter the [18F]FDG uptake rate. When a glutaminase inhibitor, 0.5mM 6-diazo-5-oxo-L-norleucine (DON), was added under the normal glucose condition, [18F]FDG uptake rate decreased. Acetyl-L-carnitine (1mM), which decreased [18F]FDG uptake rate, reversed this DON-induced decrease in [18F]FDG uptake rate in the cerebral cortex. These results suggest that acetyl-L-carnitine can be used for the production of releasable glutamate rather than as an energy source in the brain.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acetylcarnitine / physiology*
  • Animals
  • Antimetabolites, Antineoplastic / pharmacology
  • Brain / diagnostic imaging*
  • Brain / pathology*
  • Cerebral Cortex / metabolism
  • Diazooxonorleucine / pharmacology
  • Fluorodeoxyglucose F18 / pharmacokinetics
  • Glucose / pharmacology
  • Glutamic Acid / metabolism
  • Male
  • Models, Biological
  • Radiography / methods*
  • Rats
  • Rats, Sprague-Dawley
  • Time Factors
  • Tomography, Emission-Computed

Substances

  • Antimetabolites, Antineoplastic
  • Diazooxonorleucine
  • Fluorodeoxyglucose F18
  • Glutamic Acid
  • Acetylcarnitine
  • Glucose